• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向蛋白降解的 PROTACs:一种有前途的癌症治疗策略。

Target protein degradation by protacs: A budding cancer treatment strategy.

机构信息

Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.

Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.

出版信息

Pharmacol Ther. 2023 Oct;250:108525. doi: 10.1016/j.pharmthera.2023.108525. Epub 2023 Sep 9.

DOI:10.1016/j.pharmthera.2023.108525
PMID:37696366
Abstract

Cancer is one of the most common causes of death. So, its lethal effect increases with time. Near about hundreds of cancers are known in humans. Cancer treatment is done to cure or prolonged remission, and shrinkage of the tumor. Cytotoxic agents, biological agents/targeted drugs, hormonal drugs, surgery, radiotherapy/proton therapy, chemotherapy, immunotherapy, and gene therapy are currently used in the treatment of cancer but their cost is high and cause various side effects. Seeing this, some new targeted strategies such as PROTACs are the need of the time. Proteolysis targeting chimera (PROTAC) has become one of the most discussed topics regarding cancer treatment. Few of the PROTAC molecules are in the trial phases. PROTACs have many advantages over other strategies such as modularity, compatibility, sub-stoichiometric activity, acting on undruggable targets, molecular design, and acts on intracellular targets, selectivity and specificity can be recruited for any cancer, versatility, and others. PROTACs are having some unclear questions on their pharmacokinetics, heavy-molecular weight, etc. PROTACs are anticipated to bring about a conversion in current healthcare and will emerge as booming treatments. In this review article we summarize PROTACs, their mechanism of action, uses, advantages, disadvantages, challenges, and future aspects for the successful development of potent PROTACs as a drug strategy.

摘要

癌症是最常见的死亡原因之一。因此,它的致死效应随着时间的推移而增加。目前已知人类有近百种癌症。癌症的治疗目的是治愈或延长缓解期,并缩小肿瘤。细胞毒性药物、生物制剂/靶向药物、激素药物、手术、放疗/质子治疗、化疗、免疫疗法和基因疗法目前都用于癌症治疗,但它们的成本很高,且会引起各种副作用。鉴于此,一些新的靶向策略,如 PROTACs,是当前的需求。蛋白水解靶向嵌合体(PROTAC)已成为癌症治疗领域讨论最多的话题之一。一些 PROTAC 分子正在临床试验阶段。PROTACs 比其他策略具有许多优势,如模块化、兼容性、亚化学计量活性、针对不可成药靶点、分子设计以及针对细胞内靶点,可针对任何癌症招募选择性和特异性,多功能性等。PROTACs 在其药代动力学、分子量较大等方面存在一些不明确的问题。预计 PROTACs 将带来当前医疗保健的转变,并将成为热门的治疗方法。在这篇综述文章中,我们总结了 PROTACs 的作用机制、用途、优势、劣势、挑战和未来方面,以成功开发出有效的 PROTACs 作为药物策略。

相似文献

1
Target protein degradation by protacs: A budding cancer treatment strategy.靶向蛋白降解的 PROTACs:一种有前途的癌症治疗策略。
Pharmacol Ther. 2023 Oct;250:108525. doi: 10.1016/j.pharmthera.2023.108525. Epub 2023 Sep 9.
2
Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules.基于抗癌PROTAC分子的药物化学最新进展及治疗潜力
Curr Med Chem. 2023;30(14):1576-1622. doi: 10.2174/0929867329666220803112409.
3
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.蛋白水解靶向嵌合体(PROTACs)是血液系统恶性肿瘤的新兴治疗药物。
J Hematol Oncol. 2020 Jul 27;13(1):103. doi: 10.1186/s13045-020-00924-z.
4
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.新型靶向蛋白降解策略和有前景的机会:克服癌症耐药性的创新治疗方法。
Pharmacol Ther. 2023 Apr;244:108371. doi: 10.1016/j.pharmthera.2023.108371. Epub 2023 Mar 5.
5
Proteolysis-targeting chimeras (PROTACs) in cancer therapy.蛋白水解靶向嵌合体(PROTACs)在癌症治疗中的应用。
Mol Cancer. 2022 Apr 11;21(1):99. doi: 10.1186/s12943-021-01434-3.
6
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation.同价、三价和共价 PROTAC 技术:蛋白降解的新兴策略。
J Med Chem. 2022 Jul 14;65(13):8798-8827. doi: 10.1021/acs.jmedchem.2c00728. Epub 2022 Jun 28.
7
Small-molecule PROTACs: novel agents for cancer therapy.小分子 PROTACs:癌症治疗的新型药物。
Future Med Chem. 2020 May;12(10):915-938. doi: 10.4155/fmc-2019-0340. Epub 2020 Apr 9.
8
Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development.蛋白水解靶向嵌合体:一种有前途的癌症治疗技术,可深入了解肿瘤的发展。
Cancer Lett. 2022 Jul 28;539:215716. doi: 10.1016/j.canlet.2022.215716. Epub 2022 Apr 30.
9
[Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].[PROTACs及其他策略诱导的蛋白质降解:迈向有前景的药物]
Biol Aujourdhui. 2021;215(1-2):25-43. doi: 10.1051/jbio/2021007. Epub 2021 Aug 16.
10
In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.用于靶向癌症治疗的原位白蛋白结合和酯酶特异性裂解的BRD4降解PROTAC
Biomaterials. 2023 Apr;295:122038. doi: 10.1016/j.biomaterials.2023.122038. Epub 2023 Feb 7.

引用本文的文献

1
Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs.基于 Cereblon 的 PROTAC 的合成、生物学评价及临床试验
Commun Chem. 2025 Jul 29;8(1):218. doi: 10.1038/s42004-025-01598-9.
2
Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers.靶向突变型p53的药物发现及p53突变型癌症的纳米治疗策略进展
Biomolecules. 2025 May 26;15(6):763. doi: 10.3390/biom15060763.
3
Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons.
探索PROTACs在癌症治疗中的应用:进展、挑战与未来展望
Food Sci Nutr. 2025 Feb 1;13(2):e70011. doi: 10.1002/fsn3.70011. eCollection 2025 Feb.
4
PROteolysis-Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives.白血病中的蛋白酶靶向嵌合体(PROTACs):概述与未来展望。
MedComm (2020). 2024 Jun 5;5(6):e575. doi: 10.1002/mco2.575. eCollection 2024 Jun.
5
PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy.PD-1/PD-L1 的翻译后修饰及其 PROTACs 在改善癌症免疫治疗中的应用。
Front Immunol. 2024 Apr 4;15:1392546. doi: 10.3389/fimmu.2024.1392546. eCollection 2024.
6
Insights from the protein interaction Universe of the multifunctional "Goldilocks" kinase DYRK1A.多功能“金发姑娘”激酶DYRK1A的蛋白质相互作用领域的见解
Front Cell Dev Biol. 2023 Oct 12;11:1277537. doi: 10.3389/fcell.2023.1277537. eCollection 2023.